PainReform (NASDAQ:PRFX) Shares Down 3.9% – What’s Next?

PainReform Ltd. (NASDAQ:PRFX)’s stock price was down 3.9% on Monday. The stock traded as low as $0.8720 and last traded at $0.8843. Approximately 68,895 shares were traded during trading, a decline of 81% from the average daily volume of 370,412 shares. The stock had previously closed at $0.92.

Analysts Set New Price Targets

PRFX has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a research note on Friday, July 17th. Wall Street Zen raised shares of PainReform to a “sell” rating in a report on Saturday, August 1st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, PainReform presently has an average rating of “Sell”.

PainReform Stock Up 0.7%

The stock has a 50-day moving average of $0.99 and a 200 day moving average of $1.51. The stock has a market cap of $770,820.00, a PE ratio of -0.00 and a beta of 1.08.

PainReform (NASDAQ:PRFX) last posted its quarterly earnings results on Thursday, September 3rd. The company reported ($1.13) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million for the quarter.

PainReform Company Profile

PainReform Ltd. (NASDAQ: PRFX) is a clinical-stage specialty pharmaceutical company focused on developing therapies for the management of acute postoperative pain. The company’s approach is designed to provide prolonged local pain relief while potentially reducing reliance on opioid medications after surgery.

PainReform’s lead product candidate, PRF-110, is an investigational extended-release formulation of ropivacaine, a local anesthetic. The product is designed to be administered at the surgical site and gradually release the anesthetic over an extended period, with the goal of providing sustained pain control during the early recovery period following surgery.

Founded in Israel, PainReform has pursued the clinical development of its product candidates for potential use in postoperative pain management markets, including the United States and other international markets.